BioAtla (NASDAQ:BCAB – Get Free Report) and CEL-SCI (NYSE:CVM – Get Free Report) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their institutional ownership, risk, analyst recommendations, dividends, profitability, valuation and earnings.
Insider and Institutional Ownership
77.2% of BioAtla shares are held by institutional investors. Comparatively, 12.1% of CEL-SCI shares are held by institutional investors. 11.5% of BioAtla shares are held by insiders. Comparatively, 16.2% of CEL-SCI shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.
Analyst Ratings
This is a breakdown of recent ratings and price targets for BioAtla and CEL-SCI, as provided by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| BioAtla | 0 | 1 | 1 | 0 | 2.50 |
| CEL-SCI | 0 | 0 | 0 | 0 | 0.00 |
Volatility and Risk
BioAtla has a beta of 1.14, indicating that its stock price is 14% more volatile than the S&P 500. Comparatively, CEL-SCI has a beta of 0.69, indicating that its stock price is 31% less volatile than the S&P 500.
Valuation & Earnings
This table compares BioAtla and CEL-SCI”s gross revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| BioAtla | N/A | N/A | -$123.46 million | ($1.70) | -0.27 |
| CEL-SCI | N/A | N/A | -$26.92 million | ($0.51) | -0.82 |
CEL-SCI is trading at a lower price-to-earnings ratio than BioAtla, indicating that it is currently the more affordable of the two stocks.
Profitability
This table compares BioAtla and CEL-SCI’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| BioAtla | N/A | -187.30% | -96.33% |
| CEL-SCI | N/A | -228.43% | -100.46% |
Summary
BioAtla beats CEL-SCI on 8 of the 11 factors compared between the two stocks.
About BioAtla
BioAtla, Inc., a clinical-stage biopharmaceutical company, develops specific and selective antibody-based therapeutics for the treatment of solid tumor cancer. The company's lead clinical stage product candidates include mecbotamab vedotin (BA3011), a conditionally active biologic (CAB) antibody-drug conjugate (ADC), which is in Phase II clinical trial for treating undifferentiated pleomorphic sarcoma and non-small cell lung cancer (NSCLC); and ozuriftabmab vedotin (BA3021), a CAB ADC that is in Phase II clinical trial for the treatment of melanoma and squamous cell cancer of the head and neck. It is also developing Evalstotug (BA3071), a CAB anti-cytotoxic T-lymphocyte-associated antigen 4 antibody, which is in Phase II clinical trial for treating melanoma, carcinomas, and NSCLC; and BA3182, a bispecific candidate that is in Phase 1 study for the treatment of adenocarcinomas, as well as BA3361, which is in preclinical studies for treating multiple tumor types. The company was founded in 2007 and is headquartered in San Diego, California.
About CEL-SCI
CEL-SCI Corporation, a clinical-stage biotechnology company, engages in the research and development of immune system therapy for the treatment of cancer and other diseases in the United States. The company's lead immunotherapy is Multikine, which has completed Phase 3 clinical trials for the potential treatment of certain head and neck cancers. It is also developing products based on its proprietary technology Ligand Epitope Antigen Presentation System (LEAPS) technology, a patented T-cell modulation process that stimulates the human immune system to fight bacterial, viral, parasitic infections, autoimmune conditions, allergies, transplantation rejections, and cancer. In addition, the company's product pipeline includes CEL-2000; CEL-4000; and CEL-5000, which are LEAPS-based product candidates in preclinical trials for the treatment of rheumatoid arthritis disease. CEL-SCI Corporation was incorporated in 1983 and is headquartered in Vienna, Virginia.
Receive News & Ratings for BioAtla Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioAtla and related companies with MarketBeat.com's FREE daily email newsletter.
